Among our numerous research efforts aimed at improving care for those with MS are:
Descriptions of current trials, eligibility and contacts are listed in our Clinical Trials section: Our current clinical trials for MS include: The OSU Multiple Sclerosis Center is offering add-on therapy for female MS patients with one or more relapses within the last twelve months. This is a multicenter, randomized, parallel-group, double-blind study to compare the efficacy, tolerability and safety of 8 mg estriol administered orally once daily versus placebo in female patients with relapsing-remitting multiple sclerosis. The OSU Multiple Sclerosis Center is offering disease modifying therapy for MS patients with one or more relapses within the last twelve months. This is a multinational, multicenter, randomized, parallel-group, double-blind study to compare the efficacy, tolerability and safety of 0.5 mg and 1.25 mg fingolimod (FTY720) administered orally once daily versus placebo in patients with relapsing-remitting multiple sclerosis. Combination Therapy Using CellCept® and Rebif® in the Early Treatment of Multiple Sclerosis Copaxone/Avonex Combination Therapy in RRMS (CombiRx-Phase III) The OSU Multiple Sclerosis Center is offering disease modifying therapy for treatment naive MS patients with at least two exacerbations (relapses/flare ups) in the last three years. This is a Multi-Center, Double-Blind, Randomized Study Comparing the Combined Use of Interferon Beta-1a and Glatiramer Acetate to Either Agent Alone in Patients with Relapsing Remitting Multiple Sclerosis (CombiRx-Phase III). The OSU Multiple Sclerosis Center is offering disease modifying therapy for MS patients. This is a phase II, multi-center, randomized, double-blind, placebo-controlled, study to evaluate the safety tolerability and efficacy of add-on cladribine tablet therapy with Rebif® New Formulation in subjects with active disease. This is for patients with relapsing-remitting MS and secondary progressive MS (with superimposed relapses) who have experienced at least one relapse while receiving Rebif® for at least 48 weeks prior to screening. Fampridine-SR for the treatment of spasticity in MS Patients The OSU Multiple Sclerosis Center is offering patients diagnosed with multiple sclerosis an opportunity to participate in a clinical research trial to study the effects of Fampridine-SR (10mg) on walking ability. This is a 14-week long trial that requires up to 10 clinic visits. All study medications and examinations are provided by the study sponsor. The OSU Multiple Sclerosis Center is doing a research study for secondary progressive MS patients. This is a phase 3, multi-center, randomized, double-blind, placebo-controlled, study to evaluate the efficacy and safety of MBP8298. Candidate Profile: Secondary Progressive MS patients who meet all study criteria. Qualified participants will receive study-related medical evaluations and investigational medication at no cost. |
The OSU Multiple Sclerosis Center is committed to providing the highest quality patient care, while performing basic, clinical and translational research with the ultimate goal of understanding disease and formulating better treatments. 
© The Ohio State University Medical Center.
410 W. 10th Avenue, Columbus, Ohio 43210
1-800-293-5123
The content of this Web site is for informational purposes only. It does not replace the advice of a physician. All material is the property of Ohio State University Medical Center. All rights reserved. Please see our disclaimer for more detail.